Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study.

Matthias PreusserTomáš KazdaEmilie Le RhunFelix SahmMarion SmitsJens GemptJohan Af KoekkoekAngelo F MontiMarcell CsanadiJános György PitterHelen BulbekBeatrice FournierCaroline QuoilinThierry GorliaMichael WellerGiuseppe Minnitinull null

Published in: Trials (2024)

ClinicalTrials.gov NCT05904119. Registered before start of inclusion, 23 May 2023.

Keyphrases

phase iii
open label
clinical trial
double blind
phase ii
randomized controlled trial
placebo controlled